Stay updated on FG-3019 in Diabetic Kidney Disease Clinical Trial
Sign up to get notified when there's something new on the FG-3019 in Diabetic Kidney Disease Clinical Trial page.

Latest updates to the FG-3019 in Diabetic Kidney Disease Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0. The page still displays a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check17 days agoChange DetectedA site-wide NIH banner announces a transition to using “Super Intelligence” in place of “Artificial Intelligence” across NIH content.SummaryDifference1%

- Check24 days agoChange DetectedThe footer’s site revision changed from v3.7.1 to v3.7.2, while the page remains a 403 error screen.SummaryDifference0.2%

- Check31 days agoChange DetectedThe site revision label in the footer changes from v3.7.0 to v3.7.1; the page remains a 403 Forbidden error page.SummaryDifference0.2%

- Check45 days agoChange DetectedRelevant study descriptors and history entries have been removed from the record, including the investigational drug pamrevlumab (FG-3019) and several disease/condition terms related to diabetes and kidney disease, along with administrative dates. This alters how the study is categorized and surfaced in the registry, affecting searchability and interpretation by users.SummaryDifference17%

- Check52 days agoChange DetectedThe page revision has been updated from v3.6.6 to v3.7.0, indicating a new version of the study page was published.SummaryDifference0.1%

Stay in the know with updates to FG-3019 in Diabetic Kidney Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FG-3019 in Diabetic Kidney Disease Clinical Trial page.